Walleye Capital
NERV icon

Walleye Capital’s Minerva Neurosciences NERV Stock Holding History

Walleye Capital’s Portfolio NERV Stock Details NERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,078
Closed -$49 – 1456
2021
Q1 		$49 Sell
2,078
-5,405
-72% -$135K ﹤0.01% 1067
2020
Q4 		$140 Buy
+7,483
New +$188K 0.01% 777

Other funds holding NERV

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Walleye Capital's NERV Position: Q2 2021 in Review

Walleye Capital sold out of Minerva Neurosciences (NERV) in Q2 2021, closing a stake of 2,078 shares — an estimated $49 sold.

Walleye Capital first reported a position in NERV in Q4 2020 and held it in 2 quarters. The position peaked at $140 in Q4 2020. 68 funds tracked by Wall St. Rank hold NERV as of Q2 2021.

  • Walleye Capital reported no remaining Minerva Neurosciences position as of Q2 2021 after selling out during the quarter.
  • Walleye Capital sold 2,078 Minerva Neurosciences shares in Q2 2021, an estimated $49.
  • Walleye Capital first reported a position in Minerva Neurosciences in Q4 2020 and held it in 2 quarters.
  • Walleye Capital's Minerva Neurosciences position peaked at $140 in Q4 2020.
  • 68 funds tracked by Wall St. Rank held Minerva Neurosciences as of Q2 2021.

Based on Walleye Capital's 13F filing for Q2 2021, filed 16 Aug 2021.